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Induction of humoral responses to HIV at mucosal compartments without inﬂammation is important for
vaccine design.We developed chargedwax nanoparticles that efﬁciently adsorb protein antigens and are
internalized by DC in the absence of inﬂammation. HIV-gp140-adsorbed nanoparticles induced stronger
in vitro T-cell proliferation responses than antigen alone. Such responses were greatly enhanced whenvailable online 9 December 2010
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antigen was co-adsorbed with TLR ligands. Immunogenicity studies in mice showed that intradermal
vaccination with HIV-gp140 antigen-adsorbed nanoparticles induced high levels of speciﬁc IgG. Impor-
tantly, intranasal immunization with HIV-gp140-adsorbed nanoparticles greatly enhanced serum and
vaginal IgG and IgA responses. Our results show that HIV-gp140-carrying wax nanoparticles can induce
strong cellular/humoral immune responseswithout inﬂammation andmaybeof potential use as effective
V vacucosal immunity
accines
mucosal adjuvants for HI
. Introduction
The HIV pandemic continues to be a major global health prior-
ty, and while there has been good progress in the development
f antiretroviral drugs that have contributed to longer survival of
nfected individuals, prospects of an effective vaccine against HIV
emain largely elusive [1,2]. Different strategies to induce effec-
ive immune responses to HIV have been attempted in both animal
nd humanmodels but with little success and controversial results
3,4], although someprotective responses have been reported [5,6].
critical goal of HIV vaccination is the induction of mucosal
umoral immune responses. This is predicatedon theproductionof
ntibodies (Abs)with capacity of hindering the entrance of HIV and
ts subsequent interaction with target cells at mucosal sites either
y viral neutralization, aggregation, or Fc receptormediatedmech-
nisms [7]. Because HIV antigens (Ags) alone induce very low if any
mmune responses, the use of adjuvants is of paramount impor-
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tance. Adjuvants being molecules, compounds or macromolecular
complexes that boost the potency and longevity of speciﬁc immune
responses to Agwith little toxicity and long-lasting immune effects
[8]. Biodegradable nanoparticles (NP, <700nm) have been stud-
ied extensively as vehicles for delivery of Ag to antigen presenting
cells (APCs) making them good adjuvant candidates [9–14]. NP can
enhance the effectiveness of Ag uptake, which then increases Ag
delivery to intracellular compartments of APC such as dendritic
cells (DCs) and macrophages [15]. Hence, NP may increase Ag pre-
sentation capacity, thus boosting cellular and humoral immune
responses.
The Ag delivery capacity of NP has been shown both in vitro and
in vivo for a wide array of Ags such as tetanus toxoid [16], Neisseria
meningitides [17],Bacillus anthracis [18], andHIVAgs [19–22]. These
studies provide evidence that NP may be an important tool for Ag
delivery and subsequent inductionof cellular andhumoral immune
responses, critical for development of vaccines. However, success
in the development of NP as delivery systems of vaccines has been
previously hampered by their low level of colloidal stability and
wide limitations in manufacturing scale-up.
Open access under CC BY license.We have developed NPmade of yellow carnauba (YC) wax with
high colloidal stability, low cost and scalable manufacture that
would provide a rapid product development pathway. These YC-
wax NP can efﬁciently adsorb Ags such as tetanus toxoid (TT)
and the trimeric form of HIV Ag CN54-gp140 (gp140), and are
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eadily internalized by APC with subsequent induction of cellu-
ar and humoral immune responses both in vitro and in vivo. In
articular, Ag-adsorbedNP enhanced T-cell proliferation responses
n human PBMC (TT) and mouse splenocytes (HIV gp140). Also,
p140-adsorbed NP greatly enhanced serum IgG and IgA after sys-
emic immunization and, more importantly, induced high levels of
aginal IgG and IgA after intranasal immunization.
. Materials and methods
.1. Particle production
Solid lipid NP were prepared using a low pressure melt-
mulsify-chill (MEC) process. A molten yellow carnauba (YC) wax
Koster Keunen, Watertown, CT) was dispersed into a hot aque-
us emulsiﬁer solution under control shear and then cooled to
ield a stable dispersion of solid lipid NP. For the preparation of
uorescence NP, the oil-soluble ﬂuorescent dye Pyrromethene-
67A (emission wavelength 546nm, Exciton, Dayton, OH) was
ncapsulated in the NP. Cationic, anionic and non-ionic emulsiﬁers
omprised of long carbon chains were used to stabilize and also
odify the surface charge of the NP.
Particle size was determined by photon correlation spec-
roscopy using a Brookhaven BI90 Plus (Brookhaven Instruments,
oltsville, NY). The zeta (Z) potential (ameasure of the surface elec-
rical charge) of the NP and Ags was measured in 1mM KCl by
hase analysis light scattering using aMalvern Zetasizer NanoZS90
Malvern Instruments, Malvern, UK).
Particle morphology was analyzed by electron microscopy.
erial dilutions of the NP in nanopure water were dispensed in
00nl drops onto a silicon chip, and left to dry. Samples were kept
n the sputtering chamber at 5×102 mbar for about 4h, and then
putter-coatedwith15nMgold.All imageswere takenat20kV, and
t variousmagniﬁcations using aHitachi S3500N scanning electron
icroscope.
NP colloidal stability was determined by storing 10% solid NP
ispersions in glass vials at 5 ◦C and 25 ◦C. Particle size and zeta
otential were measured over a 12 month period as described
bove. For viscosity assessment, NP suspensions were stored in
25ml plastic bottles for the length of the stability studies and
he viscosity measured at different time points using a Brookﬁeld
iscometer LVT (Brookﬁeld Engineering Labs, Middleboro, MA).
pindle #4 (low viscosity sample spindle) was placed directly in
he sample, and speed setting 6 was used for all measurements.
.2. Antigens
A clade CHIV-1 envelope clone p97CN54was originally isolated
rom a Chinese patient [23] and was made available by H. Wolf
ndR.Wagner, University of Regensburg, Germany. Trimeric gp140
gp120 plus the external domain (ED) of gp41), designated CN54
p140, was produced as a recombinant product in CHO cells and
anufactured to GMP speciﬁcation by Polymun Scientiﬁc, Vienna,
ustria. Bovine serum albumin (BSA) and TT were obtained from
igma–Aldrich, Ayrshire, UKandStatens Serum Institute, Denmark,
openhagen, respectively.
.3. Antigen adsorption to nanoparticles
Antigens were adsorbed to NP by means of electrostatic inter-
ction after mixing 750g of Ag in 1ml solution with 56.2l of
1% solids NP solution, and incubated at room temperature for
0min. To determine binding of Ag to the NP, the Z potential
f NP was tested before and after protein adsorption, since pro-
eins modify the NP surface charge. Adsorption was also tested
y Bradford assay, and for gp140 a speciﬁc anti-gp140 ELISA was9 (2011) 1258–1269 1259
performed. Because the NP are made of wax material, it was not
possible to spin down the NP for further testing of unbound Ag
present in the supernatant, therefore a different protocol had to be
used. After incubation of NP with Ag, the mix was spun at 4000× g
for 10min using a 1,000,000MW cut-off Vivaspin ﬁlter (Sartorius
Stedim Biotech, Goettingen, Germany). Antigen alone was spun in
parallel to control for the amount of Ag retained in the ﬁlter. After
centrifugation, the NP were retained in the ﬁlter and the amount
of Ag present in the ﬁltrate was then tested by Bradford and ELISA
assays. To determine the amount of Ag adsorbed to NP, the amount
of Ag detected in the colorimetric assays was calculated as a per-
centage of the amount of Ag alone recovered after ﬁltration.
Co-adsorption of Ag with the TLR-9 ligand CpGB or PolyI:C
was performed using the YC-Brij700-chitosan NP, which are posi-
tively charged. CpGB (EuroﬁnsMWGOperon, Ebersberg, Germany)
and Poly (I:C) (Invivogen, San Diego, CA) was added to the NP-Ag
complex at 4.25g/ml ﬁnal concentration and incubated for an
additional 30min. CpGB and Poly (I:C) binding was assessed using
the PicoGreen dsDNA and RiboGreen dsRNA quantitation reagents
(Invitrogen Ltd., Paisley, UK).
2.4. Isolation and culture of human dendritic cells
Buffy coats obtained from healthy volunteers were used for
separation of mononuclear cells (MNC) by density gradient cen-
trifugation using ﬁcoll-hypaque (Histopaque, Sigma). Monocytes
were separated from non-adherent cells by adherence to plas-
tic using complete medium (CM: RPMI-1640 plus 10mM HEPES,
2mM l-glutamine, 100 IU/ml penicillin, 100g/ml streptomycin,
all from Sigma) supplemented with 0.5% AB pooled human serum
(PHS, Dynal Biotech, Ullernchausseen, Norway). Adherent cells
were then cultured for 4 days with 15ml CM supplemented with
5% PHS that contained 25ng/ml GM-CSF and 30ng/ml IL-4 (R&D
Systems, Inc., Minneapolis, MN). Completemediumwith cytokines
was replaced and after 3 days the cells were recovered and tested
for cell morphology by optical microscopy, and for DC phenotype
by immunoﬂuorescence and ﬂow cytometry.
2.5. Optical microscopy
Cells were placed in glass-bottom culture dishes (MatTek, Co.,
Ashland, MA) in CM plus GM-CSF and IL-4. The microscope and
stage were enclosed within a heated (37 ◦C) chamber (Solent Sci-
entiﬁc, UK) and cells were cultured in 5% CO2 in air. Images were
captured using an Olympus IX71 inverted ﬂuorescencemicroscope
equippedwith a Hamamatsu C4742-95 digital camera, using a 20×
objective with an additional 1.6× adaptor. Captured images were
analyzed using Image Pro Plus software (Media Cybernetics, USA).
2.6. Immunoﬂuorescence and ﬂow cytometry
AssessmentofDCdifferentiation/enrichment andmodulationof
DC phenotype before and after treatment with gp140-adsorbed NP
was determined by single cell surface immunostaining using mon-
oclonal Abs against lineagemarkers and co-stimulatorymolecules.
Cells were stained with FITC-labeled anti-CD14, -CD3, -CD19, -
CD56, and -DC-SIGN; PE-labeled anti-CD11c, -CD40, -CD80, -CD83,
-CD86 and CCR7, and PE-Cy5-labeled-HLA-DR mAb. Ten thousand
events were acquired in a FACSort Becton-Dickinson cytometer
(San Jose, CA), and the samples were analyzed using the CellQuest
software version 3.3 (Becton Dickinson, PaloAlto, CA).2.7. Nanoparticle cell internalization and intracellular tracking
Nanoparticle-Ag cell internalization was tested by ﬂow cytom-
etry and confocal microscopy using Pyrromethene-567A-labeled
1 cine 2
N
i
l
d
o
t
t
d
c
a
w
1
b
m
c
a
G
a
(
D
a
g
t
5
f
t
c
2
n
G
A
t
s
I
c
m
c
p
2
2
w
w
w
(
t
t
c
a
u
i
w
c
c
a
t260 M.A. Arias et al. / Vac
P. Cells (DC or THP-1 cells) were cultured at 5×105/well
n a 24-well plate with CM plus 5% PHS. Pyrromethen-567A-
abeled Ag-adsorbed NP were added to the cells at a ﬁnal
ilution in CM corresponding to 5g/ml gp140 and incubated
vernight.
For ﬂow cytometry analysis, the cells were recovered after cul-
ure,werewashedwith PBS, andﬁxedwith 1.5% formaldehyde. Ten
housand events were acquired and analyzed by ﬂow cytometry as
escribed above.
For confocal analysis, DC were resuspended in 50l of PBS
ontaining 5.0g/ml red ﬂuorescent Alexa Fluor-594 wheat germ
gglutinin (WGA, Invitrogen) to stain the cell membrane. Cells
ere incubated for 10min at 37 ◦C, then washed and ﬁxed for
0min. After ﬁxation, the ﬁxing buffer was completely removed
y centrifugation, and the cells counterstained with Vectashield
ounting medium (Vector Laboratories, Peterborough, UK) that
ontained DAPI. Cells were analyzed by confocal microscopy using
LSM 510 laser scanning microscope (Carl Zeiss MicroImaging,
ermany).
Tracking of NP-AgwithinDC endolysosomeswas assessed using
lysosome speciﬁc dye on DC cultured on Lab-tek chamber slides
Nalge Nunc International, Naperville, IL) pre-coated with gelatin.
endritic cells were cultured overnight in CM containing IL-4
nd GM-CSF. The CM was replaced with serum-free medium, and
p140-adsorbed NP at 5g/ml Ag, ﬁnal concentration were added
o the wells together with 100M Lysotracker Red (DND-99, Abs
77nm; Em 590nm, Invitrogen) prewarmed at 37 ◦C in serum-
ree medium. The cells were incubated for 2h at 37 ◦C after which
he serum-free medium was replaced with CM, and analyzed by
onfocal microscopy.
.8. In vitro activation of human DC by antigen-adsorbed
anoparticles
Differentiated immature DC were cultured in the presence of
M-CSF+ IL-4, with or without gp140-adsorbed NP (5g/ml ﬁnal
g concentration). Modulation of DC activation/maturation was
ested after 24, 48, and 72h by determining cell surface expres-
ion of CD40, CD54, CD80, CD83, CD86, CCR7, and HLA-class
I using immunostaining and ﬂow cytometry, and by assessing
ytokine/chemokine release in the cell culture supernatants by
ultiplex assay. DC cultured in CM only were used as a negative
ontrol of stimulation, and in the presence of 25ng/ml TNF- as a
ositive control.
.9. Cell proliferation assays
.9.1. Human cells
Human MNC (2×105 cells/200l) were stimulated for 5 days
ith12.5g/mlTT inCMplus5%PHS.Becausenearly100%of theTT
as adsorbed to the NP (see Section 3.1), an amount of 12.5g/ml
as used for both NP-adsorbed and free Ag. Free CpGB and Poly
I:C) were used at a ﬁnal concentration of 4.25g/ml, which was
he same amount used for co-adsorption with Ag onto NP. Phy-
ohaemaglutinin (PHA, 5g/ml, SIGMA) was used as a positive
ontrol of stimulation, and CM alone as a negative control. BSA-
dsorbed NP, TT plus CpGBwithout NP, or chitosan alonewere also
sed as controls. Cell proliferation was assessed by incorporation
ntoDNAof [3H]Td (GEHealthcare, Buckinghamshire, UK). The cells
ere pulsed with 0.5Ci [3H]Td/well 18h before harvesting, and
ounts per minute (c.p.m.) determined in a liquid scintillation 
ounter (1450 Microbeta Plus, Wallac Oy, Turku, Finland). Prolifer-
tion response was calculated as the mean± SD of the c.p.m. from
hree replicates.9 (2011) 1258–1269
2.9.2. Murine cells
Splenocytes from gp140-immune Balb/cmicewere cultured for
3 days in the presence of 5g/ml gp140, either free or adsorbed to
NP. Concanavalin-A (5g/ml, Sigma) was used as a positive con-
trol of stimulation. After 48h, the cells were pulsed as for human
cells, and 18h later the cellswere harvested and the c.p.m. counted.
Proliferation responsewas expressed as stimulation index (PI), cal-
culated by dividing the mean of the c.p.m. from three replicates of
the experimental by the mean c.p.m. of the not-stimulated cells.
2.10. ELISA
2.10.1. Detection of antigen-speciﬁc antibody responses
Determination of speciﬁc TT serum IgG, speciﬁc gp140 serum
IgG, IgG1, IgG2a, and IgA, as well as speciﬁc gp140 IgG and IgA in
vaginal and nasal lavages, and in feces was performed by ELISA.
ELISA plates (MaxiSorp, Nalge-Nunc International, Rochester, NY)
were coated overnight at room temperature with 4g/ml TT or
5g/ml gp140 in PBS. Blocking was performed for 1h at 37 ◦C
with PBS containing 1% BSA. Serially diluted samples were incu-
bated for 1h at 37 ◦C. Bound IgG, IgG1, and IgG2a were detected
by incubation for 1h at 37 ◦C with goat anti-mouse Ig-HRP (AbD
Serotec, Kidlington, Oxford, UK), or with biotinylated goat anti-
mouse IgA Ab (SouthernBiotech, Birmingham, AL) to detect bound
IgA. An ampliﬁcation step was performed to detect IgA by incubat-
ing the plates with HRP-streptavidin conjugate (R&D Systems) for
1h at 37 ◦C. Plateswere developed by adding tetramethylbenzidine
(TMB, Pierce-Endogen, Woburn, MA) and incubating the plates in
the dark. The reaction was stopped using 1.0N H2SO4, and optical
densities (O.D.) read at 450nm. Amix of pre-immune samples was
run in 6-replicates per plate and the cut-off calculated (after sub-
tracting the blank) as the mean of these 6 values plus 3 SD, except
for that of feces where 5 SD were used.
2.10.2. Detection of gp140
ELISA plates were coatedwith 1g/ml in PBS of afﬁnity puriﬁed
sheep anti-HIV-1-gp120 polyclonal antibody (AAlto Bio Reagents,
Dublin, Ireland) and incubated overnight at room temperature.
Blocking was performed for 1h at 37 ◦C with Buffer 1 (PBS plus 2%
skimmedmilk powder). gp140 standards and samples were added
to the wells and incubated for 2h at 37 ◦C. Detection of gp140 was
performed by incubation for 1h at 37 ◦C with 2g/ml 5F3 anti-
gp140humanmAb inBuffer2 (PBSsupplementedwith2%skimmed
powder milk, 5% porcine serum and 0.5% Tween-20), followed by
incubation for 1h at 37 ◦C with goat anti-human IgG-HRP (South-
ernBiotech) in Buffer 2. Plateswere developedwith TMB for 20min
in the dark. The reaction was stopped with 1.0N H2SO4 and O.D.
read at 450nm.
2.11. Detection of cytokines/chemokines by multiplex assay
Human cytokines/chemokines in cell culture supernatantswere
detected using an in-house multiplex assay following a protocol
recommended by themanufacturers (R&D) as previously described
[24].
2.12. In vivo immunizations with tetanus toxoid and gp140
2.12.1. Animals
Female Balb/c mice, 6–8 week old, were obtained from HarlanOlac Ltd., UK. Mice were kept at the Biological Research Facility,
St. George’s University of London. All procedures were performed
in accordance with the United Kingdom’s Home Ofﬁce standards
under the Animals Scientiﬁc Procedures Act, 1986, and approved
by the School’s Ethical Review Committee.
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Fig. 1. Physicochemical characterization of nanoparticles and binding to antigen. (A) Scanning electron microscopy of YC-wax NP: a, YC-SDS; b, YC-NaMA; c, YC-
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ercentage of Ag bound to NP after subtracting the amount detected on the ﬁltrate
he percentage of Ag bound to NP with respect to Ag alone taken as 100%.
.12.2. Immunization protocol and sample collection
Mice were inoculated i.d. with 12.5g (TT) or 20g (gp140) in
total volume of 100l in sterile saline on both dorsal ﬂanks fol-
owing a prime-boost-boost protocol at 4 (TT) and 3 (gp140) week
ntervals. For i.n. immunization, 20g gp140with orwithout NP in
maximum volume of 25l were gently dispensed in the animal’s
ostrils after isoﬂuorane-induced anaesthesia. Antigen-adsorbed
P were prepared the same day of immunization. Fresh compo-
ents of the formulations were used in these experiments because
heywere performed inparallelwith theNP colloidal stability stud-
es (see Fig. 1B). These studies suggested nonetheless that similara, particle size distribution (PSD); b, zeta potential (Z); and c, viscosity. (C) Zeta
gp140 to NP measured by Bradford assay. Numerical values in the ﬁgure are the
lone. (E) Detection by ELISA of gp140 adsorbed to NP. Values inside bars represent
results would be obtained using the same formulation over time.
Alum-Ag complex was prepared by mixing equal volumes of Ag
and Alum solution (Imject Alum, Pierce, Rockford, IL), and mixed
by rotation for 30min at room temperature.
Blood samples were collected before priming, 1–3 days before
boosting, and at 4 (TT) and 3 (gp140) weeks after the last boost.
◦Serumwas separated from clotted blood and stored at −80 C until
further use. Vaginal sampleswere collected by ﬂushing 30l of PBS
three times into the vagina of anaesthetized animals, pooled and
supplementedwith 8l of a 25× protease inhibitor cocktail (Roche
Diagnostics, Manheim, Germany). Samples were incubated for
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0min on ice and then spun at 14,000 rpm for 10min. Supernatants
ere collected and stored at−80 ◦C. Eight fecal pellets/mousewere
ollected, weighed and mixed with 4× their weight of 1× protease
nhibitor cocktail. Samples were homogenized to dissolve the pel-
ets and incubated on ice for 1h. The samples were spun twice at
4,000 rpm for 10min, and cleared supernatants stored at −80 ◦C.
asal sampleswere obtained after sacriﬁce of the animals by ﬂush-
ng the nasal cavity with 300l of PBS containing 1× protease
nhibitor cocktail. The samples were stored at −80 ◦C.
.13. Statistical analyses
Analyses were performed using GraphPad Prism, version 4.00
GraphPad Software). Linear data was expressed as means± SEM,
hereas logarithmic datawas expressed as geometricmeans±95%
onﬁdence interval. Statistical differences between groups were
alculated using one-way ANOVA with Tukey’s multiple compar-
son posttest to compare groups by pairs. Differences between
roups in relation to time were analyzed by two-way ANOVA with
onferroni’s posttest for comparison of pairs. Paired Student’s t-
est was used to compare two groups. Differences were considered
igniﬁcant at P≤0.05.
. Results
.1. Characterization of YC-wax nanoparticles
Multiple types of YC-NP emulsiﬁed with different surfactants
ere screened for low cell toxicity, efﬁcient cellular uptake, and
ood protein adsorption (data not shown). Three different YC-NP
ere selected that met these criteria: YC-SDS (yellow carnauba-
odium dodecil sulphate), YC-NaMA (sodium myristate acetate),
ndYC-Brij700-chitosan. The latterNPwasemulsiﬁedwithBrij700,
surfactant with a long carbon chain (C18) that contains 100
thylenoxide (EO) units, and then mixed with medium molecular
eight chitosan during the oil-in-watermelting process to provide
he NP surface with a positive charge.
The zeta potential (Z) of the different YC-NP, a measurement in
V of the magnitude of repulsion or attraction between particles,
as: YC-SDS, −47.7; YC-NaMA, −64.1; and YC-Brij700chitosan,
19.5. The size of the NP ranged between 387.0 and 675.0nm,
ith mean size± SD for each NP as follows: YC-SDS, 406.5±27.94,
= 6; YC-NaMA, 478.8±100.9, n=5; and YC-Brij700-chitosan,
88.0±123.0, n=2. The NP polydispersity index (PDI) was YC-
DS: 0.21±0.033; YC-NaMA: 0.17±0.05; and YC-Brij700chitosan
.41±0.23. Representative SEM pictures of YC-SDS, YC-NaMA, and
C-Brij700chitosan particles are shown in Fig. 1A. Nanoparticles
howed high stability at 5 ◦C and 25 ◦C in terms of particle size,
P, and viscosity for up to 12 months after preparation (Fig. 1B),
emonstrating good colloidal stability.
Zeta potential of the Ags, as expected, varied widely depending
n the pH due to the amphoteric characteristics of the proteins.
owever, all three Ags (BSA, TT, and gp140) showed negative ZP
t pH ranging between 7 and 8. Interestingly, whereas the ZP at
his pH interval was about −10mV for BSA and gp140, that of TT
eached −30mV. These results suggest that, at physiological pH,
dsorption of Ags to the NP may vary depending on both NP and
rotein surface charge. However, all three Ags bound to anionic
nd cationic NP (data not shown and Fig. 1C). Binding of gp140
o negatively (YC-SDS and YC-NaMA) and positively (YC-Brij700-
hitosan) charged NP is shown in Fig. 1C as indicated by the change
n ZP ofNP after incubationwith gp140.Webelieve that association
f theseAgswith theYC-NPmaybedominatedbybothelectrostatic
nd hydrophobic interactions [25].9 (2011) 1258–1269
To further conﬁrm adsorption of gp140 to NP, Bradford assay
and gp140-speciﬁc ELISAwere also performed. Both assays showed
that YC wax NP bound gp140 with high efﬁciency (Fig. 1D and E).
Binding of BSA and TT to wax NP, assessed by Bradford, was also
highly efﬁcient (data not shown).
3.2. YC-wax nanoparticles are internalized by antigen presenting
cells
In vitro human monocyte-derived DC were generated using a
standardized protocol as described by Henderson et al. [26] with
minor modiﬁcations. Blood-derived monocytes were isolated by
plastic adherence and showed typical spiky cell membrane pro-
jections following 7 days of culture in the presence of GM-CSF and
IL-4, as shown in Fig. 2A. Immunostaining and ﬂow cytometry anal-
ysis of 11 different DC isolations showed that 91.6%±3.8 (range:
84.7–96.6%) of cells had a DC phenotype with very low or negative
expression of CD14, and high expression of CD11c, HLA-class II Ags,
and DC-SIGN. CD40 and CD86 were consistently highly expressed
on these cells,whereasCD80and thematurationmarkerCD83were
expressed at low levels (Fig. 2B). The non-DC present in these iso-
lates were consistently B-lymphocytes (Fig. 2B inset). The three
YC-wax NP were studied for NP intracellular uptake. Both naked
and TT- and gp140-adsorbed YC NP were readily internalized by
DC as demonstrated by ﬂow cytometry and confocal microscopy
(Fig. 2C and D, respectively). Once internalized, YC NP were local-
ized in endolysosomes (Fig. 2E). Cellular uptake of YC-wax NP was
more efﬁcient and was more uniformly distributed within the cell
population than that of polystyrene nanobeads (Fig. 2F). Here, 100%
of THP-1 cells internalized YC-wax NP whereas about 70–90% of
these cells internalized polystyrene NP.
3.3. gp140-adsorbed YC-wax NP do not induce activation of DC
neither by modulating cell surface activation/maturation markers
nor release of cytokine/chemokines
Human monocyte-derived DC were stimulated with gp140-
adsorbed YC-waxNP (YC-SDS, YC-NaMA, and YC-Brij700-chitosan)
and expression of the cell surfacemarkers CD40, CD54, CD80, CD83,
CD86, CCR7, and HLA-class II Ags was assessed by immunoﬂuores-
cence and ﬂow cytometry after 24, 48, and 72h post-stimulation.
There was no effect on the expression of these molecules, even
when tested at an extended time point of 72h (data not shown).
Likewise, there was no cytokine/chemokine induction by YC-wax-
gp140-adsorbedNP (data not shown). NakedNP also did not induce
any DC activation.
3.4. YC-wax-nanoparticles enhance T-cell proliferation responses
to antigen in human PBMC and mouse splenocytes
We sought to determine whether YC-wax NP would enhance
the T-cell proliferation responses to Ag. Since there are some lim-
itations for the use of gp140 to induce human T-cell proliferation
in vitro such as the lack of immune response in HIV unexposed
healthy volunteers, and the anergic status of many HIV-infected
individuals, TTwas used as amodel Ag. Hence,we tested the capac-
ity of TT-adsorbed YC-wax NP to enhance T-cell proliferation in
fresh PBMC from healthy volunteers. As shown in Fig. 3A, YC-wax
NP enhanced T-cell proliferation to TT. This response was indepen-
dent of the type of particles since both negatively (YC-wax SDS and
YC-wax NaMA) and positively (YC-wax Brij700-chitosan) charged
NP enhanced T-cell proliferation responses to TT (P<0.0001). This
response was speciﬁc for TT as YC-wax NP adsorbed with the
irrelevant Ag BSA did not induce T-cell proliferation (Fig. 3A). Inter-
estingly, when the TLR-9 ligand CpGB (Fig. 3B) but not the TLR-3
ligand Poly I:C (data not shown) was co-adsorbed with TT to YC-
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Fig. 2. Analysis of gp140-adsorbed nanoparticle internalization by antigen presenting cells. (A) Phase contrast microscopy of DC. (B) Phenotype of in vitro differentiated
human DC. Dot plot shows the gated DC population analyzed. Left histograms represent the isotype control. Inset depicts the staining for CD19+ showing about 10% of B
cells. n represents the number of blood donors with the mean± SD plus range of cells with a DC phenotype. (C) Flow cytometry analysis of gp140-adsorbed wax NP uptake
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ey DC. Left histograms correspond to cells without NP. (D) DC gp140-wax NP (YC-N
ucleus; Green: ﬂuorescent gp140-adsorbed YC-NaMA NP. Values at the top left co
very section. (E) Lysosomal localization of gp140-adsorbed YC-NaMA NP within D
omparison of wax NP uptake by THP-1 cells of two different types of NP: polysty
uorescent NP.rij700-chitosan NP, the T-cell proliferation response was further
nhanced (P<0.0001). To conﬁrm that this effect was due to the
o-adsorption of both TT Ag and CpGB to the YC-wax NP, sev-
ral controls were performed (Fig. 3B). Speciﬁcally, to test thathown) uptake as demonstrated by confocal microscopy. Red: cell membrane; Blue:
of each quadrant represent the distance in m from top to bottom of the cell after
low color represents the overlapping of green (NP) plus red (lysosomes) colors. (F)
left) vs YC-wax NaMA (right). Top right panel represents the MFI of cells withoutthe enhancing effect was not due to cell activation induced by
the chitosan present on the YC-wax Brij700-chitosan NP, both chi-
tosan alone and together with TT (in the absence of NP) were
also assessed. Results show that neither chitosan nor TT+chitosan
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Fig. 3. Enhancement of T-cell proliferation responses to antigen after adsorption to nanoparticles. Human T-cell proliferation response to (A) TT-adsorbed NP, and (B) TT
after co-adsorption to YC-Brij700-chitosan NP with CpGB. TT was used at 12.5g/ml and CpGB at 4.25g/ml. Results shown are the mean± SEM of c.p.m. values of three
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*ifferent donors performed in triplicate cultures. ***P<0.001. (C) Mouse splenocyte
ere stimulated in vitro with gp140-adsorbed NP at 5g/ml ﬁnal Ag concentration
riplicate. Mean comparisons were performed by one-way ANOVA.
nhanced T-cell proliferation (Fig. 3B). In addition, although CpGB
nduced T-cell proliferation on its own, this induction was signiﬁ-
antly lower than that inducedbyTT-CpGBco-adsorbedNP. Further
onﬁrmation of the enhancing effect on T-cell proliferation by co-
dsorption of TT plus CpGB onNP, was demonstratedwhen instead
f using TT, the irrelevant Ag BSAwas co-adsorbed toNPwith CpGB
Fig. 3B).
To test whether NP could enhance T-cell proliferative responses
o gp-140, splenocytes from gp140-immunized mice were used
n vitro. Splenocytes were cultured in the presence of Ag alone
3r gp140-adsorbed NP and the incorporation of H[Td] into DNA
easured after three days of culture. gp140-adsorbed NP but not
aked NP enhanced splenocyte proliferative responses to gp140
P<0.001)(Fig. 3C), indicating that such an effect was not due to
he particles themselves.
ig. 4. In vivo humoral immune responses to antigen-adsorbed nanoparticles. Kinetics o
TT) and 8 (gp140) mice were immunized three times with (A) 12.5g TT and (B) 20g
ontrol of immunization. Serum samples were obtained before each immunization and
esults shown are the mean± SEM of one experiment (TT) and two aggregated experime
osttest to comparemeans by pairs. *P<0.05; **P<0.01; ***P<0.001. (C) Kinetics of speciﬁ
nd sampled as in (B), and the serum samples were tested for speciﬁc-gp140 IgA end-po
erum IgG1/IgG2a ratio. Serum samples obtained 30 days after the third immunization w
he aggregated data of IgG1/IgG2a Log10 ratio values of two different experiments for the
*P<0.01; ***P<0.001.eration response to gp140-adsorbed NP. Splenocytes from gp-140 immunizedmice
lts shown are the mean± SEM of the SI of two different experiments performed in
3.5. YC-wax NP enhance systemic humoral immune responses to
antigen in vivo
Experiments were performed in mice using gp140-adsorbed
NP to determine whether NP can enhance humoral responses to
Ag in vivo. Similar experiments were performed previously using
TT and results showed that systemic immunization with all three
NP enhanced serum levels of speciﬁc anti-TT IgG after the ﬁrst
boost (60 days), which were comparable to those induced by Alum
(Fig. 4A). Such levels were not enhanced further after the third
immunization (90 days), and became comparable to those induced
by TT alone, which by itself is a very potent Ag [27], suggesting
that the role of NP was to increase the kinetics of serum anti-
TT IgG. For induction of speciﬁc anti-gp140 IgG and IgA, animals
were immunized i.d. with gp140 following a prime-boost-boost
f speciﬁc serum IgG after i.d. immunization with (A) TT and (B) gp140. Groups of 3
gp140 either free or adsorbed to NP. Ag adsorbed to Alum was used as a positive
30 days after the last immunization, and tested for IgG end-point titers by ELISA.
nts (gp140). Mean differences were analyzed by two-way ANOVA with Bonferroni
c serum IgA after i.d. immunization with gp140. Groups of 8mice were immunized
int titers by ELISA. Mean comparisons were analyzed as in (B). (D) gp140-speciﬁc
ere tested by ELISA for gp140-speciﬁc IgG1 and IgG2a end-point titers. Plotted are
groups shown in the ﬁgure. Means were compared by one-way ANOVA. *P<0.05;
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Fig. 5. Systemic and mucosal humoral immune responses to gp140-adsorbed nanoparticles after intranasal immunization. (A) and (B) Kinetics of serum and vaginal IgG
and IgA levels. Groups of 5 animals were immunized i.n. with 20g of gp140 either free or adsorbed to YC-NaMA NP. Serum and vaginal lavages were obtained before each
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**P<0.001. (C) Levels of IgG and IgA in nasal lavage after second boost. Animals we
acriﬁced and the nasal cavity washed with saline. Samples were tested for gp140-
-test.
rotocol at 30 day intervals. Serum samples were taken before
ach immunization and 30 days after the last boost, and the lev-
ls of IgG and IgA were tested by gp140-speciﬁc ELISA. gp140
lone induced signiﬁcant levels of IgG but these levels were much
igher when the Ag was adsorbed to NP (Fig. 4B). Such IgG levels
ere comparable to those induced by Alum (day 60), and differ-
nces were already observable following a single prime (day 30).
lateau IgG levels were already observed after ﬁrst boost (day 60,
ig. 4B).
Serum speciﬁc anti-gp140 IgA was only detected after the sec-
nd immunization (60 days) but the titers were not high because
he maximum end-point titer levels of IgA detected under these
mmunization conditions were 282.4±88.4 (log10 2.45±1.95).
C-Brij700chitosan-gp140 but not YC-SDS-gp140 nor YC-NaMA-
p140promoted signiﬁcant speciﬁc-gp140 IgA titers (P<0.05) after
hree immunizations (90 days). Such effect was comparable to that
f Alum at the same time point (P<0.05). However, the effect of
P as a whole on serum speciﬁc-gp140 IgA after i.d. immunization
as low because the kinetics and magnitude of speciﬁc-gp140 IgA
esponses promoted by Alum after the ﬁrst boost (60 days) was
igniﬁcantly superior to those of NP (Fig. 4C).
To test whether YC-wax NP modulated T-helper cell responses,
he gp140 speciﬁc IgG1/IgG2a ratio was also determined by ELISA.
f note, gp140 alone induced an IgG response that was biased
owards a Th2 phenotype. Such a response did not appear to beG and IgA end-point titers by ELISA. Means were compared by two-way ANOVA.
unized as in (A) and (B), and 21 days after the last immunization the animals were
c IgG and IgA end-point titers as for (A) and (B). Means were compared by paired
modulated by Alum, YC-wax NaMA or YC-wax Brij700-chitosan
(Fig. 4D). However, YC-wax SDS appeared to induce a more bal-
anced Th1/Th2 response (Fig. 4D).
3.6. YC-wax-nanoparticles enhance mucosal humoral responses
to gp140
To test whether NP were also capable of enhancing mucosal
humoral responses to gp140, mice were immunized nasally with
either Ag alone or adsorbed to YC-wax-NaMA NP, and the levels
of IgG and IgA were determined in serum and mucosal ﬂuids. We
chose YC-NaMA NP for i.n. immunization ﬁrst because, these NP
showed a signiﬁcant enhancement of systemic humoral immune
responses to both TT and gp140 across the i.d. immunizations (see
Fig. 4A and B). Second, NaMA is a naturally occurring surfactant,
present inmanynatural oils and,more importantly, in humannasal
ﬂuid [28]. Alum was not used as a positive control of adjuvanticity
for i.n immunization due to the intrinsic inﬂammatory role of Alum
salts, since part of their mechanism of action is to induce necrotic
and damaged cells at the site of injection [29], an effect that would
be incompatible with nasal immunization.
Antigen alone failed to induce any response (Fig. 5). In contrast,
there was a steady increase over time in both serum IgG and IgA in
response to gp140 adsorbed to YC-NaMA NP (Fig. 5A). These levels
did not seem to reach a plateau after the second boost, as it was
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bservedwith serum IgG after intradermal immunization. Notably,
igh levels of IgA were also observed in vaginal secretions, with a
oderate increase in IgG (Fig. 5B). In addition, IgG and IgA levels
ere also detected in the nasal lavages of these mice (Fig. 5C). No
ntibody inductionwasobserved in feces (data not shown). Of note,
he IgG1/IgG2a ratio in serum was very close to 1 (1.57±0.079),
hich was lower than that induced by intradermal immunization
ith gp-140-YC-wax NaMA, suggesting that the type of T-helper
mmune response induced by NP may change depending on the
oute of immunization.
. Discussion
We have developed a highly stable NP vaccine delivery system
ade of YC-wax material. These NP have a low cost of production
hat is easily scalable. Indeed, similar particles are alreadymanufac-
ured inkilogramquantities for use in the cosmetics industry. These
eatures, together with their capacity to efﬁciently adsorb protein
gs, to be readily internalized by APC, and to enhance immune
esponses to Ag both in vitro and in vivo,make themgood potential
elivery systems for vaccines, and in particular that of HIV vaccines
or the developing world.
Manipulation of the YC-waxNP surface chargewith surfactants,
rovides optimal ﬂexibility to adsorb different types of Ag [30]. In
his study, Ags as diverse as TT, BSA, and HIV-1 gp140 were efﬁ-
iently adsorbed to both negatively and positively charged NP. In
ddition, the surface chargeﬂexibility also facilitated co-adsorption
f more than one molecule onto the NP surface as shown by co-
dsorption of Ag with CpGB and PolyI:C. After screening a large
ange of wax NP, three different types were selected according to
heir low toxicity, Ag adsorption efﬁciency, and cell internalization
roﬁle, i.e., YC-SDS, YC-NaMA, and YC-Brij700-chitosan. The ﬁrst
woNPhad a net negative charge,whereas the third onewas highly
ositive, a characteristic deﬁned by the presence of the carbohy-
rate chitosan. We determined adsorption of gp140 to these NP by
hree different methods: Z potential, Bradford assay, and ELISA. All
hreemethods provided strong evidence of effective Ag adsorption
o NP. In addition, the ELISA assay suggested that antigenicity was
naffected, which may represent an advantage over Ag encapsula-
ion as reported previously for a form of HIV-gp120 by Singh et al.
31].
Flowcytometryandconfocalmicroscopy studies clearly showed
hat Ag-adsorbed YC NP were readily internalized by APC, and that
hese NP were subsequently tracked within endolysosomes, sug-
esting that the NPmay have the capacity to deliver Ag into the Ag
rocessing and presentation compartment.
Naked YC-wax NP did not induce cytokine/chemokine produc-
ion or up-regulation of co-stimulatory molecules on DC in vitro,
or induced visible signs of inﬂammation after both mucosal and
ystemic administration in vivo (data not shown). This lack of DC
ctivation by naked NP is important especially if used at the uro-
enital tract, because such cell activation would induce mucosal
nﬂammation at this level that may facilitate HIV infection.
Antigen-adsorbed YC-wax NP (TT in human PBMC and gp140
n mouse splenocytes) enhanced T-cell proliferation responses in
itro. The response to TT by human PBMC was greatly enhanced
y co-adsorption with CpGB (Fig. 3B) but not with PolyI:C (data
ot shown). CpGB on its own enhanced cellular proliferation, and
e speculate that CpGB induces non-speciﬁc proliferation of PBMC
ost likely due topolyclonal B cell activation, as has beendescribed
reviously [32]. Nevertheless, the enhanced proliferation observed
ith co-adsorption of TT+CpGB particles was signiﬁcantly greater
han the additive effect of TT plus CpGB alone.
Nanoparticles enhanced serum humoral immune responses
o Ag in vivo. Animals immunized i.d. with gp140-adsorbed NP9 (2011) 1258–1269 1267
enhanced serum IgG production after a single prime, and this
effect was comparable or better than that induced by Alum. Sur-
prisingly, CpGB co-adsorbed to NP with either TT or gp140 did
not enhance antibody production further (data not shown). Alum
salts are well known strong parenteral adjuvants which are com-
ponents of an array of licensed human vaccines [8]. However, to
date they have not been successfully used for mucosal vaccina-
tion. Reactogenicity of Alum salts is an important characteristic of
their adjuvanticity. Their mechanism of action has been associated
with induction of local uric acid crystals [33] and inﬂammasome
activation with release of IL-1 by macrophages and DC [34,35].
Such reactogenicity is deemed too potent for mucosal use [36]. We
do not know the mechanism of in vivo enhancement of humoral
responses by gp140-adsorbed NP but since NP alone showed little
if any reactogenicity in the skin of mice when compared to that
induced by Alum, the mechanism of action may be highly differ-
ent to that of Alum salts. The efﬁcient cell internalization of NP
and their subsequent localization within the endolysosome com-
partment in the absence of co-stimulatory molecule up-regulation
and cytokine/chemokine production by DC clearly suggest a differ-
ent mechanism. Thus, the lack of Alum-type reactogenicity of NP
makes them good potential candidates for mucosal immunization.
This may be particularly important where potential inﬂammation
and edema have been associatedwith induction of Bell’s palsy [37].
Although no adverse effects were observed on nasal administra-
tion of YC-NaMA NP in mice, further experiments will be required
to conﬁrm the safety of these NP after intranasal application in
humans, in particular the assessment of the effect of surfactants
on the nasal olfactory and respiratory epithelia. Nevertheless, the
amount of NaMA, a naturally occurring fatty acid in human nasal
ﬂuid [28], used in this formulation was very low (0.025%), and as
such the likelihood for toxicity is considered to be small.
We immunized mice with gp140-adsorbed YC-NaMA using dif-
ferent routes of immunization, including nasal, vaginal and rectal.
The responses to gp140 via vaginal and rectal mucosal compart-
ments were weak or null (data not shown). Reasons for this
unresponsiveness in these mucosas may include physical prop-
erties of mucus (pore size and rheological factors) [38], and/or
their paucity of follicle associated epithelium when compared to
nasal associated lymphoid tissue (NALT). Nasal immunization, in
contrast, potently induced both systemic and mucosal humoral
immune responses. Intranasal immunization has been described
as an effective route to induce systemic and mucosal immune
responses to Ag, in particular in the urogenital tract, with scarce
if any induction in the gut [39,40]. When mice were immunized
nasally with gp140-adsorbed NaMA NP, high levels of IgG and
IgA were induced in serum as well as vagina, and titers were
still increasing following three immunizations. IgA levels in serum
induced by i.n. immunization were around one to two orders
of magnitude higher than those induced by i.d. immunization,
suggesting that the NP themselves do not inherently drive IgA
switching. We believe it is more likely that the route of immu-
nization has an important role at inducing serum IgA as has been
previously suggested [39,40].We speculate that gp140-speciﬁc IgA
plasmacells induced in thenasal cavitymayhome to spleenor bone
marrow. It is worth noting that levels of gp140-speciﬁc IgG and IgA
were also enhanced in the nasal cavity. This suggests that wax NP
may also have utility for delivering of immunogens against respi-
ratory pathogens.M-cells of NALT are thought to play an important
role in the uptake of NP in rodents and humans and are absent in
vaginal and rectal mucosa [41–43].The nasal route has been extensively studied not only for vacci-
nation purposes [44–47] but also for the delivery of drugs [48], and
NP have been used nasally to induce immune responses to TT [49]
andHIV [50]. Inductionof systemic andmucosal immune responses
to HIV after nasal immunization of mice [51,52], guinea pigs [51]
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nd macaques [5] with HIV-gp120 Ag has been described previ-
usly. In the latter, serum and vaginal Ab responses were induced
fter nasal immunization only when followed by one or two intra-
uscular boosts. These levels were highly enhanced in vagina after
hallenge with SHIV, suggesting that the nasal priming induced
ffective memory responses at mucosal level [5]. In our mouse
odel, three nasal immunizationswere enough to induce high lev-
ls of IgG and IgA in serum and vagina. It remains to be conﬁrmed
hether this immunization protocol with NPwill work similarly in
acaques or humans, or whether these Abs would be neutralizing.
herefore, further studies are warranted that assess homologous
nd heterologous immunization protocols to determine the feasi-
ility of using these NP, as effective delivery systems of HIV Ags, in
he development of mucosal vaccination in humans.
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